| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.3 | 1e-08 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.23 | 3e-06 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.22 | 5e-06 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.099 | 0.04 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.094 | 0.06 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.077 | 0.1 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.049 | 0.3 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.044 | 0.3 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.045 | 0.4 |